On Sept. 2, 2025, OMass Therapeutics announces an exclusive collaboration and license agreement with Genentech, a member of the Roche Group, for the rights to develop and commercialize OMass’ preclinical oral small molecule program for inflammatory bowel disease.

Under the terms of the agreement, OMass will receive an upfront payment of $20 million, plus additional potential preclinical, development, commercial and net sales milestone payments of more than $400 million. OMass is also eligible for tiered royalties on net sales.

Under the collaboration, OMass will lead the initial preclinical development of the program until candidate selection. Genentech will be responsible for clinical development, regulatory activities, manufacturing and commercialization.